Method for treating moderate and severe psoriasis using recombinant Anti-il-23p19 antibody
HK40134784APending Publication Date: 2026-07-10INNOVENT BIOPHARMACEUTICALS (HANGZHOU) CO LTD
Patent Information
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- INNOVENT BIOPHARMACEUTICALS (HANGZHOU) CO LTD
- Filing Date
- 2026-05-13
- Publication Date
- 2026-07-10
AI Technical Summary
Technical Problem
Existing biological agents for treating silver eyebrow disease have a short duration of effect after discontinuation, requiring frequent injections from patients, which increases their burden and costs. Furthermore, the demand for low-cost, high-efficiency biological agents in China has not been met.
Method used
A long-half-life recombinant anti-IL-23p19 antibody was used, and a dosing regimen of once every 12 weeks was adopted to maintain the therapeutic effect and reduce the frequency of injections.
Benefits of technology
The use of long-half-life antibodies has achieved a long-lasting effect in treating silver eyebrow disease, reducing the frequency of injections, alleviating the burden on patients, and improving their quality of life.
✦ Generated by Eureka AI based on patent content.
Abstract
Belongs to the field of disease treatment, and relates to application of a recombinant anti-IL-23p19 antibody in treatment of moderate and severe psoriasis and a method for treating moderate and severe psoriasis in a subject, and the method comprises the step of applying an effective amount of the anti-IL-23p19 antibody to the subject.
Need to check novelty before this filing date? Find Prior Art